The Evolution of Tyrosine Kinase Inhibitor Therapy: Improving Outcomes in Patients with Newly Diagnosed Chronic Myelogenous Leukemia
Chronic myelogenous leukemia (CML) is a hematologic malignancy initiated by a translocation event that results in the fusion of the breakpoint cluster region (BCR) of chromosome 22 with the Abelson leukemia oncogene (ABL) tyrosine kinase on chromosome 9 in bone marrow stem cells. This chromosomal abnormality is known as the Philadelphia (Ph) chromosome.1,2
Katherine Mandock, PharmD, BCPS, Scott Soefje, PharmD, MBA, BCOP, FCCP, Val R. Adams, PharmD, FCCP, BCOP
Current Practice in the Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting in Adults
The impact of chemotherapy-induced nausea and vomiting (CINV) for the patient with cancer cannot be overemphasized. Uncontrolled CINV has been cited as one of the greatest fears among people undergoing cancer treatments.1,2 Advances in antiemetic therapy in the past 20 years have improved patient experiences and outcomes. Despite this, the majority of patients with cancer will experience CINV during their chemotherapy treatments.1,3-6 In particular, nausea is less well controlled than vomiting.
Results 1 - 3 of 3